Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis

American Journal of Clinical Pathology

Volumn 124, Issue 6, 2005, Pages 838-845

  Hassan, Raffit ^a   Laszik, Zoltan G ^b   Lerner, Megan ^b,c   Raffeld, Mark ^a   Postier, Russell ^b   Brackett, Daniel ^b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chronic pancreatitis; Immunohistochemistry; Mesothelin; Pancreatic, ampullar, and common bile duct cancer

Indexed keywords

CELL SURFACE PROTEIN; MESOTHELIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5B2; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT CANCER; CHRONIC PANCREATITIS; COMMON BILE DUCT; CONTROLLED STUDY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MESOTHELIUM CELL; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TISSUE FIXATION; VATER PAPILLA; VATER PAPILLA CARCINOMA;

EID: 28444437055     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/F1B64CL7H8VJKEAF     Document Type: Article

References (24)

1. Ahmedin J, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Bramhall S, Dunn J, Neoptolemos JP. Epidemiology of pancreatic cancer. In: Beger HG, Warshaw A, Carr-Locke DL, et al, eds. The Pancreas. Boston, MA: Blackwell Scientific; 1998:889-906.
3. Kern S, Hruban R, Hollingsworth MA, et al. A white paper: the product of a pancreas cancer think tank. Cancer Res. 2001;61:4923-4932.
4. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463-473.
5. Wade TP, Prasad CN, Virgo KS, et al. Experience with distal bile duct cancers in the US Veterans Affairs hospitals. J Surg Oncol. 1997;64:242-245.
6. Nagorney DM, Donohue JH, Farnell MB, et al. Outcomes after curative resections of cholangiocarcinomas. Arch Surg. 1993;128:871-879.
7. Howe JR, Klimstra DS, Moccia RD, et al. Factors predictive of survival in ampullary carcinoma. Ann Surg. 1998;228:87-94.
8. Allema JH, Reinders ME, van Gulik TM, et al. Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. Surgery. 1995;117:247-253.
9. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol. 2002;160:1239-1249.
10. Ryu B, Jones J, Blades NJ, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res. 2002;62:819-826.
11. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862-3868.
12. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93:136-140.
13. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody reactive with ovarian cancers and normal mesothelium. Int J Cancer. 1992;50:373-381.
14. Yamaguchi N, Hattoris K, Oh-eda M, et al. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994;269:805-808.
15. Kojima T, Oh-eda M, Hattori K, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDN A. J Biol Chem. 1995;270:21984-21990.
16. Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279:9190-9198.
17. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol. 1992;16:259-268.
18. Chang K, Pastan I, Willingham M. Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. Int J Cancer. 1992;51:548-554.
19. Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 2003;16:192-197.
20. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418-1428.
21. Frierson HF, Moskaluk CA, Powell SM, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003;34:605-609.
22. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10:3937-3942.
23. Van Heek NT, Maitra A, Koopmann J, et al. Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther. 2004;3:651-656.
24. Swierczynski SL, Maitra A, Abraham SC, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol. 2004;35:357-366.